Register Login

Zymeworks Inc (ZYME)

(10% Negative) Zymeworks Inc (ZYME) Announces Delay in Ziihera Development Timeline Due to Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment

Full text
Register to leave comments
  • News bot Jan. 29, 2026, 6:51 p.m.

    📋 Zymeworks Inc (ZYME) - Clinical Trial Update

    Filing Date: 2026-01-12

    Accepted: 2026-01-12 16:34:50

    Event Type: Clinical Trial Update

    Event Details:

    Zymeworks Inc (ZYME) Announces Clinical Trial Update Zymeworks Inc (ZYME) provided an update on its clinical development programs. Clinical Development Highlights:
    • Drug Program: Ziihera
    • Clinical Stage: Phase 3
    • Update Type: Trial Timeline Adjustment
    • Primary Factors: Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
    • Collaboration: China • Company
    • Updated Timeline: November 2025, December 31, 2025
      • expected in mid-2026
      • targeting ADC incorporating a novel pan-RAS inhibitor payload) into clinical studies only with partnerships and collaborations and/or external funding becoming available; and, • Beyond 2026
      • targeting novel pathways in areas of significant unmet medical need. The Company’s complementary therapeutic platforms and fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutics. These capabilities have been further leveraged through strategic partnerships with global biopharmaceutical companies. For information about Zymeworks, visit www.zymeworks.com and follow @ZymeworksInc on X. Cautionary Note Regarding Forward-Looking Statements This press release includes “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933

    🔬 Clinical Development Pipeline (Zymeworks Inc):

    Product Type Development Stage Therapeutic Area Source
    ZW191 DRUG Phase PHASE1 Advanced Solid Tumors ClinicalTrials.gov
    Zanidatamab DRUG Phase PHASE2 Breast Cancer ClinicalTrials.gov
    ZW251 DRUG Phase PHASE1 Hepatocellular Carcinoma ClinicalTrials.gov
    Tamoxifen DRUG Phase PHASE2 Breast Cancer ClinicalTrials.gov
    Letrozole DRUG Phase PHASE2 Breast Cancer ClinicalTrials.gov
    ZW171 DRUG Phase PHASE1 Mesothelin-expressing Advanced Cancers ClinicalTrials.gov
    Gemcitabine DRUG Phase PHASE3 Biliary Tract Neoplasms ClinicalTrials.gov
    Cisplatin DRUG Phase PHASE3 Biliary Tract Neoplasms ClinicalTrials.gov
    Niraparib DRUG Phase PHASE3 Biliary Tract Neoplasms ClinicalTrials.gov
    Binimetinib DRUG Phase PHASE3 Biliary Tract Neoplasms ClinicalTrials.gov
    Encorafenib DRUG Phase PHASE3 Biliary Tract Neoplasms ClinicalTrials.gov
    Neratinib DRUG Phase PHASE3 Biliary Tract Neoplasms ClinicalTrials.gov
    Trastuzumab DRUG Phase PHASE3 Biliary Tract Neoplasms ClinicalTrials.gov
    Ivosidenib DRUG Phase PHASE3 Biliary Tract Neoplasms ClinicalTrials.gov
    Futibatinib DRUG Phase PHASE3 Biliary Tract Neoplasms ClinicalTrials.gov
    ZW49 DRUG Phase PHASE1 HER2-expressing Cancers ClinicalTrials.gov
    ZW25 DRUG Phase PHASE2 Endometrial Cancer ClinicalTrials.gov

    💼 Business Developments:

    • Partnership
    • Acquisition
    • Licensing
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: Zymeworks Inc
    • Ticker Symbol: ZYME

Search

News categories